These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18580968)

  • 1. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
    Yokoyama T; Iwado E; Kondo Y; Aoki H; Hayashi Y; Georgescu MM; Sawaya R; Hess KR; Mills GB; Kawamura H; Hashimoto Y; Urata Y; Fujiwara T; Kondo S
    Gene Ther; 2008 Sep; 15(17):1233-9. PubMed ID: 18580968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
    Kanaya N; Kuroda S; Kakiuchi Y; Kumon K; Tsumura T; Hashimoto M; Morihiro T; Kubota T; Aoyama K; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Mizuguchi H; Urata Y; Fujiwara T
    Mol Ther; 2020 Mar; 28(3):794-804. PubMed ID: 31991110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.
    Oh E; Hong J; Kwon OJ; Yun CO
    Sci Rep; 2018 Jan; 8(1):1420. PubMed ID: 29362367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
    Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
    Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic adenoviruses for the treatment of brain tumors.
    Gomez-Manzano C; Fueyo J
    Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
    Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
    Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo.
    Gomez-Gutierrez JG; Nitz J; Sharma R; Wechman SL; Riedinger E; Martinez-Jaramillo E; Sam Zhou H; McMasters KM
    Virology; 2016 Jan; 487():249-59. PubMed ID: 26561948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy.
    Ulasov IV; Shah N; Kaverina NV; Lee H; Lin B; Lieber A; Kadagidze ZG; Yoon JG; Schroeder B; Hothi P; Ghosh D; Baryshnikov AY; Cobbs CS
    Oncotarget; 2015 Feb; 6(6):3977-87. PubMed ID: 25738357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines.
    Sato D; Kurihara Y; Kondo S; Shirota T; Urata Y; Fujiwara T; Shintani S
    Oncol Rep; 2013 Dec; 30(6):2659-64. PubMed ID: 24065118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
    Fujiwara T; Tanaka N
    Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death.
    Alonso MM; Jiang H; Yokoyama T; Xu J; Bekele NB; Lang FF; Kondo S; Gomez-Manzano C; Fueyo J
    Mol Ther; 2008 Mar; 16(3):487-93. PubMed ID: 18253154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
    Huang P; Watanabe M; Kaku H; Kashiwakura Y; Chen J; Saika T; Nasu Y; Fujiwara T; Urata Y; Kumon H
    Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.
    Huang P; Kaku H; Chen J; Kashiwakura Y; Saika T; Nasu Y; Urata Y; Fujiwara T; Watanabe M; Kumon H
    Cancer Gene Ther; 2010 Jul; 17(7):484-91. PubMed ID: 20168351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death.
    Jiang H; Gomez-Manzano C; Aoki H; Alonso MM; Kondo S; McCormick F; Xu J; Kondo Y; Bekele BN; Colman H; Lang FF; Fueyo J
    J Natl Cancer Inst; 2007 Sep; 99(18):1410-4. PubMed ID: 17848677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.